{"TopicDetails": {"type": 0, "ccm2Id": 45032667, "cftId": 0, "identifier": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05", "title": "Strengthening regulatory capacity for supporting conduct of clinical trials", "publicationDateLong": 1652227200000, "callIdentifier": "HORIZON-JU-GH-EDCTP3-2022-01", "callTitle": "Research and Innovation actions supporting the global health EDCTP3 Joint Undertaking", "callccm2Id": 45032759, "allowPartnerSearch": true, "frameworkProgramme": {"id": 43108390, "abbreviation": "HORIZON", "description": "Horizon Europe Framework Programme (HORIZON)"}, "programmeDivision": [{"id": 43108557, "abbreviation": "HORIZON.2.1", "description": "Health"}, {"id": 43108541, "abbreviation": "HORIZON.2", "description": "Global Challenges and European Industrial Competitiveness"}], "topicMGAs": [], "tags": ["regulatory capacity", "regulatory sciences", "global health", "pharmacovigilance", "sub-Saharan Africa", "Africa", "health", "clinical trials", "clinical research", "infectious diseases"], "keywords": ["Clinical research", "Social sciences and humanities", "Medical statistics", "Public health and epidemiology", "Regulatory affairs", "Public health", "Societal Engagement", "Africa", "Global health", "Pharmacovigilance", "International Cooperation", "Clinical trials"], "flags": ["SSH", "SocietalEngagement", "Africa", "EC-WORLD"], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": [{"typeOfAction": "HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "typeOfMGA": [{"id": 43027846, "abbreviation": "HORIZON-AG", "description": "HORIZON Action Grant Budget-Based"}]}], "plannedOpeningDate": "11 May 2022", "submissionProcedure": {"id": 31094504, "abbreviation": "single-stage", "description": "single-stage"}, "deadlineDates": ["30 August 2022"]}], "latestInfos": [{"approvalDate": "Oct 7, 2022 10:57:19 AM", "lastChangeDate": "Oct 7, 2022 10:57:19 AM", "content": "<p><span lang=\"EN-IE\" style=\"font-size: 10.5pt; line-height: 107%; font-family: &quot;inherit&quot;, serif; color: rgb(51, 51, 51); border: 1pt none windowtext; padding: 0cm;\">Call </span><span lang=\"EN-IE\">HORIZON-JU-GH-EDCTP3-2022-01</span><span lang=\"EN-IE\" style=\"font-size: 10.5pt; line-height: 107%; font-family: &quot;inherit&quot;, serif; color: rgb(51, 51, 51); border: 1pt none windowtext; padding: 0cm;\"> closed on 30 August 2022. A total of 92 proposals were submitted. The breakdown per topic is:</span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01: 40 proposals&nbsp;</span><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&#10;&quot;inherit&quot;,serif;mso-bidi-font-family:Calibri;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:FR-BE\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02: 14 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03: 20 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04:&nbsp; 2 proposals<o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin: 0cm 0cm 3.75pt 18.75pt; text-indent: -18pt; line-height: normal; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;\"><!--[if !supportLists]--><span lang=\"EN-IE\" style=\"font-size:10.0pt;mso-bidi-font-size:10.5pt;font-family:Symbol;&#10;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">&middot;<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><!--[endif]--><span lang=\"EN-IE\" style=\"font-size:10.5pt;font-family:&quot;inherit&quot;,serif;color:#333333;&#10;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm;padding:0cm;&#10;mso-ansi-language:EN-IE;mso-fareast-language:FR-BE\">HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05: 16 proposals<o:p></o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size:10.5pt;line-height:107%;font-family:&quot;inherit&quot;,serif;&#10;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:&#10;&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;color:#333333;border:none windowtext 1.0pt;&#10;mso-border-alt:none windowtext 0cm;padding:0cm;mso-ansi-language:EN-IE;&#10;mso-fareast-language:FR-BE;mso-bidi-language:AR-SA\">Evaluation results are expected to be communicated on Friday 21 November 2022 at the earliest.</span></p>"}], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3418887": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 5000000}, "expectedGrants": 8, "minContribution": 600000, "maxContribution": 600000, "budgetTopicActionMap": {}}], "3418889": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04 - HORIZON-JU-CSA HORIZON JU Coordination and Support Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 1000000}, "expectedGrants": 1, "minContribution": 1000000, "maxContribution": 1000000, "budgetTopicActionMap": {}}], "3418891": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 30850000}, "expectedGrants": 5, "minContribution": 6000000, "maxContribution": 8000000, "budgetTopicActionMap": {}}], "3418893": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 22000000}, "expectedGrants": 4, "minContribution": 5000000, "maxContribution": 5000000, "budgetTopicActionMap": {}}], "3418895": [{"action": "HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01 - HORIZON-JU-RIA HORIZON JU Research and Innovation Actions", "plannedOpeningDate": "11 May 2022", "deadlineModel": "single-stage", "deadlineDates": ["30 August 2022"], "budgetYearMap": {"2022": 38030000}, "expectedGrants": 9, "minContribution": 4000000, "maxContribution": 4000000, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2022"]}, "description": "<SPAN class=\"topicdescriptionkind\">ExpectedOutcome</SPAN>:<p>This topic aims at supporting activities that are contributing to one or several of the expected impacts for this call. To that end, proposals under this topic should aim for delivering results that are directed towards and contributing to the following expected outcomes:</p><ul level=\"0\"><li>Enhanced regulatory capacity to conduct clinical trials in sub-Saharan Africa countries, complementing the work of the African Vaccine Regulatory Forum (AVAREF);</li><li>Increased common regulatory mechanisms across sub-Saharan Africa countries, including better alignment with regional standards and overarching continental mechanisms such as the African Medicines Agency;</li><li>Better equipped health systems to integrate new or improved health technologies;</li><li>Improved efficiency regarding the process of market authorisation of new or improved health technologies;</li><li>Improved efficiency of the National Regulatory Agencies (NRAs) concerning clinical trials oversight;</li><li>Lessons and principles that will help continental or regional Regulatory Agencies in sub-Saharan Africa to better define their function, frameworks and capabilities;</li><li>Stronger African ownership and leadership of clinical research in sub-Saharan Africa countries;</li><li>Better collaboration between NRAs and national and institutional research ethics committees, research integrity offices and data access committees;</li><li>Accelerated maturity towards level 4 of the Regulatory Agencies in sub-Saharan Africa.</li> </ul>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The purpose of this call for proposals is to fund projects designed to support regulatory capacity and develop technical expertise reinforcing regulatory systems in sub-Saharan Africa countries for supporting the conduct of clinical trials.</p><p>These objectives should contribute to strengthening frameworks and capabilities, including issuance of relevant permits, clinical trials oversight and clinical research pharmacovigilance and post-trial market authorisation by NRAs. The funded projects should train researchers, clinicians and Regulatory Agency authorities' personnel for an efficient and robust regulatory control system for approving the conduct of clinical trials and for a responsive clinical trials pharmacovigilance.</p><p>The proposals should address several of the following activities:</p><ul level=\"0\"><li>Desk review and mapping of the clinical research oversight and pharmacovigilance systems across the involved sub-Saharan Africa countries through country questionnaires and (virtual) participatory workshops to identify gaps and needs;</li><li>Develop approaches and provide training to develop personal and institutional capacities on clinical trial oversight and pharmacovigilance of the NRA staff, researchers, clinicians and other healthcare workers, including knowledge exchange through South-South and North-South partnerships;</li><li>NRAs should recruit at least two new staff members to be trained on clinical trials regulatory framework and be integrated, with a well-defined function and objectives, in the participating Agency in a systems approach. The new staff members should stay in the Agency team for at least two years and participate in networking events, such as the Scientific Conference on Medical Products Regulation in Africa;</li><li>Facilitate and promote harmonised regulatory pathways for clinical research and joint assessment of market authorisations in line with regional and national guidelines;</li><li>Define strategies or practices that can inform policy revisions to improve the efficiency of the NRAs, by introducing innovative systems, practices, and/or technologies that improve the quality and timelines of these bodies as regards clinical research oversight and clinical research pharmacovigilance;</li><li>Promote international cooperation in clinical research regulatory activities with regional and international regulatory harmonization bodies by transferring promising and successful innovative systems and/or technologies from other regions outside Africa and within Africa, fostering national and regional collaboration with regional and international regulatory harmonization bodies;</li><li>Strengthen linkages between regulatory functions and clinical trial registries, such as the Pan African Clinical Trials Registry (PACTR: https://pactr.samrc.ac.za/), while enforcing data sharing in compliance with global requirements;</li><li>Support already established training centres to provide both innovative clinical research training and mentorship to NRAs;</li><li>Plans to foster links between NRAs and initiatives reinforcing collaboration between NRAs and National Ethics Committees in sub-Saharan Africa.</li> </ul><p>Proposals should clearly describe the national mismatch between disease burden, research activity and level of regulation that justify the need for support. Proposals should explain the links of the proposed activities to existing regulatory initiatives, such as the Africa Vaccines Regulators Forum (AVAREF), the Pan-African Clinical Trials Registry (PACTR), the African Medicines Regulatory Harmonisation (AMRH), the African Medicines Agency (AMA) and the Regional Centres of Regulatory Excellence in Africa (RCOREs)<sup><a target=_self href=#fn1 id=r1>[1]</a></sup>. Other regional bodies to be taken into account where appropriate are the African Medicines Quality Forum (AMQF), Africa Centre for Disease Control and Prevention (Africa CDC) and Regional Economic Communities.</p><p>Particular attention should also be paid to ensuring complementarity and coherence with other activities supported by the European Union and EU Member States in the countries involved in the proposal; for example: EDCTP Regional Networks of Excellence<sup><a target=_self href=#fn2 id=r2>[2]</a></sup>, The health systems dimension of the Global Gateway investment package<sup><a target=_self href=#fn3 id=r3>[3]</a></sup>, various Team Europe initiatives such as the Team Europe initiative (TEI) on Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+) in Africa<sup><a target=_self href=#fn4 id=r4>[4]</a></sup>.</p>\n<SPAN class=\"topicdescriptionkind\">Cross-cutting Priorities</SPAN>:<p>Social sciences and humanities<br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=EC-WORLD;sortQuery=sortStatus;orderBy=asc\">International Cooperation</a><br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=SocietalEngagement;sortQuery=sortStatus;orderBy=asc\">Societal Engagement</a><br><a href=\"//ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-search;statusCodes=31094501,31094502,31094503;programCcm2Id=43108390;crossCuttingPriorityCode=Africa;sortQuery=sortStatus;orderBy=asc\">Africa</a><br></p>\n<p id=fn1><a  target=_self href=#r1>[1]</a>African Regulatory Centres of Excellence (RCOREs) were mandated by the African Medicines Regulatory Harmonization (AMRH) initiative. There are currently 11 RCOREs throughout Africa: <a href=\"https://www.nepad.org/publication/regional-centres-regulatory-excellence-rcores\">https://www.nepad.org/publication/regional-centres-regulatory-excellence-rcores</a></p><p id=fn2><a  target=_self href=#r2>[2]</a>EDCTP regional networks of excellence strengthen regional networking and provide platforms for research training and multicentre studies <a href=\"http://www.edctp.org/our-work/edctp-regional-networks-of-excellence/\">http://www.edctp.org/our-work/edctp-regional-networks-of-excellence/</a></p><p id=fn3><a  target=_self href=#r3>[3]</a>Global Gateway investment package <a href=\"https://ec.europa.eu/info/strategy/priorities-2019-2024/stronger-europe-world/global-gateway/eu-africa-global-gateway-investment-package_en\">https://ec.europa.eu/info/strategy/priorities-2019-2024/stronger-europe-world/global-gateway/eu-africa-global-gateway-investment-package_en</a> </p><p id=fn4><a  target=_self href=#r4>[4]</a><a href=\"https://ec.europa.eu/international-partnerships/news/eu1-billion-team-europe-initiative-manufacturing-and-access-vaccines-medicines-and-health_en\">Team Europe Initiative on Manufacturing and access to vaccines, medicines and medical technologies</a> (MAV+) will directly fund, starting in 2022/2023, the European Medicines Agency (EMA), African Medicine Agency AUDA-NEPAD (AMA) and the World Health Organisation (WHO).</p>", "conditions": "<p><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:11.0pt;line-height:115%;&#10;font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:&#10;Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;&#10;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi;&#10;color:#404040;mso-themecolor:text1;mso-themetint:191;mso-ansi-language:EN-US;&#10;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">General conditions</span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">1. Admissibility conditions: </span></b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;&#10;mso-bidi-font-weight:bold\">described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex A</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> and </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:&#10;Calibri;mso-bidi-theme-font:minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex E</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> of the Horizon Europe Work Programme General Annexes</span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">Proposal page limits and layout:</span></b><span lang=\"EN-US\" style=\"mso-ansi-language:&#10;EN-US\"> described in Part B of the Application Form available in the Submission System</span></p>\r\n<p>&nbsp;</p>\r\n<p>&nbsp;</p>\n<p><b><span lang=\"EN-US\">2. Eligible countries:&nbsp;</span></b></p>\r\n<p><span lang=\"EN-US\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">According to Article 110 of the Council Regulation (EU) 2021/2085, funding from the&nbsp; Global Health EDCTP3 Joint Undertaking is restricted to legal entities established in Member States or associated countries or in the constituent states of the EDCTP Association.</span></p>\r\n<p><span lang=\"EN-US\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">Constituent states of the EDCTP Association that are not Member States or associated countries are: Burkina Faso, Cameroon, Congo, C&ocirc;te d&rsquo;Ivoire, Ethiopia, Gabon, The Gambia, Ghana,&nbsp;</span><span style=\"font-family: Calibri, sans-serif; font-size: 14.6667px;\">Kenya,</span><span style=\"font-family: Calibri, sans-serif; font-size: 14.6667px;\">&nbsp;</span><span style=\"font-family: Calibri, sans-serif; font-size: 11pt;\">Mali, Mozambique, Niger, Nigeria, Senegal, South Africa, Tanzania, Uganda, United Kingdom, Zambia.</span></p>\r\n<p><span lang=\"EN-US\">A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the&nbsp;</span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\">Horizon Europe Programme Guide</a></span><span lang=\"EN-US\">.</span></p>\r\n<p>&nbsp;</p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">3. Other eligibility conditions:</span></b><span lang=\"EN-US\">&nbsp;described in&nbsp;</span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex B</a></span>&nbsp;<span lang=\"EN-US\">of the Work Programme General Annexes,&nbsp;</span>except for the specific conditions for GH EDCTP3 funding as regards&nbsp;<u>Entities eligible for funding</u>&nbsp;and&nbsp;<u>Consortium composition.</u></p>\r\n<p class=\"MsoNormal\"><i><u><span lang=\"EN-IE\">Entities eligible to participate<o:p></o:p></span></u></i></p>\r\n<p class=\"MsoNormal\" style=\"text-align: justify;\"><span lang=\"EN-IE\">Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, there is currently no appropriate context allowing the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government controlled territories of Ukraine. Therefore, such legal entities are not eligible to participate in any capacity. This criterion also applies in cases where the action involves financial support given by grant beneficiaries to third parties established in Russia, Belarus or in non-government controlled territories of Ukraine (in accordance with Article 204 of the Financial Regulation No 2018/1046).<b><u><o:p></o:p></u></b></span></p>\r\n<p class=\"MsoNormal\"><i><u><span lang=\"EN-IE\">Entities eligible for funding<o:p></o:p></span></u></i></p>\r\n<p class=\"MsoNormal\"><span lang=\"EN-IE\">To be eligible for funding, applicants must be eligible to participate and established in one of the eligible countries, i.e.<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-indent: -18pt; line-height: 12.6px;\"><span lang=\"EN-IE\">-<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span><span lang=\"EN-IE\">The Member States of the European Union, including their outermost regions;<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-indent: -18pt; line-height: 12.6px;\"><span lang=\"EN-IE\">-<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span><span lang=\"EN-IE\">The Oversees Countries and Territories (OCTs) linked to Member States<a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftn1\" name=\"_ftnref1\" title=\"\"><span class=\"MsoFootnoteReference\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">[1]</span></span></span></a><o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"text-indent: -18pt; line-height: 12.6px;\"><span lang=\"EN-IE\">-<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span><span lang=\"EN-IE\">Eligible non-EU countries:<o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left: 72pt; text-indent: -18pt; line-height: 12.6px;\"><span lang=\"EN-IE\" style=\"font-family: &quot;Courier New&quot;;\">o<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;</span></span><span lang=\"EN-IE\">Countries associated to Horizon Europe<a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftn2\" name=\"_ftnref2\" title=\"\"><span class=\"MsoFootnoteReference\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">[2]</span></span></span></a><o:p></o:p></span></p>\r\n<p class=\"MsoListParagraph\" style=\"margin-left: 72pt; text-indent: -18pt; line-height: 12.6px;\"><span lang=\"EN-IE\" style=\"font-family: &quot;Courier New&quot;;\">o<span style=\"font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: &quot;Times New Roman&quot;;\">&nbsp;&nbsp;&nbsp;</span></span><span lang=\"EN-IE\">Countries that are members of the EDCTP Association<a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftn3\" name=\"_ftnref3\" title=\"\"><span class=\"MsoFootnoteReference\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-IE\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">[3]</span></span></span></a><o:p></o:p></span></p>\r\n<p><span lang=\"EN-IE\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call conditions, or if the participation is considered essential for implementing the action by the granting authority.</span></p>\r\n<div><br clear=\"all\" />\r\n<hr align=\"left\" size=\"1\" width=\"33%\" />\r\n<div id=\"ftn1\">\r\n<p class=\"MsoFootnoteText\"><a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftnref1\" name=\"_ftn1\" title=\"\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\" style=\"font-size: 10pt; line-height: 14.2667px; font-family: Calibri, sans-serif;\">[1]</span></span></span></span></a><span lang=\"EN-US\">&nbsp;</span><span lang=\"EN-IE\">Entities from Oversees Countries and Territories (OCT) are eligible for funding under the same conditions as entities from the Member State to which the OCT in question is linked. See the&nbsp;</span><span lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\"><span lang=\"EN-IE\">Horizon Europe Programme Guide</span></a></span><span lang=\"EN-IE\">&nbsp;for a complete list of OCTs.</span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n</div>\r\n<div id=\"ftn2\">\r\n<p class=\"MsoFootnoteText\"><a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftnref2\" name=\"_ftn2\" title=\"\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\" style=\"font-size: 10pt; line-height: 14.2667px; font-family: Calibri, sans-serif;\">[2]</span></span></span></span></a><span lang=\"EN-US\">&nbsp;</span><span lang=\"EN-IE\">See list of&nbsp;</span><span lang=\"EN-US\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf\"><span lang=\"EN-IE\">Associated Countries</span></a></span><span class=\"MsoHyperlink\"><span lang=\"EN-IE\">&nbsp;and&nbsp;<a href=\"https://ec.europa.eu/info/research-and-innovation/strategy/strategy-2020-2024/europe-world/international-cooperation_en\" target=\"_blank\">International Cooperation</a></span></span><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n</div>\r\n<div id=\"ftn3\">\r\n<p class=\"MsoFootnoteText\"><a href=\"file:///C:/Users/crisaal/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/32LODOYY/Topic%20Conditions%20new.docx#_ftnref3\" name=\"_ftn3\" title=\"\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\"><span class=\"MsoFootnoteReference\"><span lang=\"EN-US\" style=\"font-size: 10pt; line-height: 14.2667px; font-family: Calibri, sans-serif;\">[3]</span></span></span></span></a><span lang=\"EN-US\">&nbsp;</span><span lang=\"EN-IE\">See the&nbsp;</span><span lang=\"EN-US\"><a href=\"http://www.edctp.org/about-us/governance/general-assembly/members-of-the-general-assembly/\"><span lang=\"EN-IE\">EDCTP website</span></a><o:p></o:p></span></p>\r\n</div>\r\n</div>\r\n<p>&nbsp;</p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b>4. Financial and operational capacity and exclusion: </b><span style=\"mso-bidi-font-weight:bold\">described in <a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex C</a> of the Work Programme General Annexes</span></p>\r\n<p>&nbsp;</p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"FR-BE\" style=\"mso-ansi-language:FR-BE\">5.&nbsp;Evaluation and award:</span></b></p>\r\n<p>&nbsp;</p>\n<div>\r\n<ul type=\"square\" style=\"margin-top: 0cm;\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Award criteria&nbsp;</span></b><span lang=\"EN-US\">&nbsp;are described in&nbsp;</span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex D</a></span><span lang=\"EN-US\">&nbsp;of the Work Programme General Annexes.</span></li>\r\n    <li class=\"MsoNormal\">\r\n    <p class=\"MsoNormal\"><strong><span lang=\"EN-US\">Scoring and thresholds</span></strong><span lang=\"EN-US\">&nbsp;are as follows:<o:p></o:p></span></p>\r\n    <p class=\"MsoNormal\" style=\"text-align: justify;\"><span lang=\"EN-IE\">Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criteria 3 (Quality and efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.<o:p></o:p></span></p>\r\n    <span lang=\"EN-IE\" style=\"font-size: 11pt; line-height: 15.6933px; font-family: Calibri, sans-serif;\">Proposals that pass the individual threshold AND the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.</span></li>\r\n</ul>\r\n</div>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Submission and evaluation      processes</span></b><span lang=\"EN-US\"> are      described in </span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex      F</a></span><span lang=\"EN-US\"> of      the Work Programme General Annexes and the </span><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\">Online      Manual</a><span lang=\"EN-US\"><o:p></o:p></span></li>\r\n</ul>\n<ul style=\"margin-top:0cm\" type=\"square\">\r\n    <li class=\"MsoNormal\"><b><span lang=\"EN-US\">Indicative timeline for      evaluation and grant agreement: </span></b><span lang=\"EN-US\">described in </span><span class=\"MsoHyperlink\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex      F</a></span><span lang=\"EN-US\"> of the Work Programme General Annexes</span><span lang=\"EN-US\"><o:p></o:p></span></li>\r\n</ul>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b style=\"mso-bidi-font-weight:normal\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">6. Legal and financial set-up of the grants: </span></b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">described in </span><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:&#10;minor-latin\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\">Annex G</a></span></span><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\"> of the Work Programme General Annexes<o:p></o:p></span></p>\r\n<p>&nbsp;</p>\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\">Specific conditions<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\">7. Specific conditions: </span></b><span lang=\"EN-US\">described in the specific topic of the Work Programme<o:p></o:p></span></p>\n<p>&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-US\" style=\"font-size:12.0pt;mso-bidi-font-size:&#10;11.0pt;line-height:115%;mso-ansi-language:EN-US\">Documents<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">Call documents:<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">Standard application form &mdash;<i style=\"mso-bidi-font-style:normal\"> call-specific application form is available in the Submission System</i><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/af/af_he-csa_en.pdf\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\">Standard application form (HE CSA)</span></a><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin\"><o:p></o:p></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color: rgb(64, 64, 64);\">Standard evaluation form </span><span lang=\"EN-US\">&mdash;<i> will be used with the necessary adaptations</i></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/temp-form/ef/ef_he-csa_en.pdf\"><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">Standard evaluation form (HE CSA)</span></a><span lang=\"EN-US\" style=\"color:#404040;&#10;mso-themecolor:text1;mso-themetint:191;mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> <o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span lang=\"EN-US\" style=\"color:#404040;mso-themecolor:text1;mso-themetint:191;&#10;mso-ansi-language:EN-US;mso-bidi-font-weight:bold\">MGA</span><b><span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;tab-stops:&#10;191.4pt\"><span class=\"MsoHyperlink\"><span style=\"mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/agr-contr/general-mga_horizon-euratom_en.pdf\">HE <span lang=\"EN-US\" style=\"mso-ansi-language:EN-US\">General MGA v1.1</span></a></span></span><span class=\"MsoHyperlink\"><span style=\"mso-ansi-language:EN-US;mso-bidi-font-weight:&#10;bold\"> <span lang=\"EN-US\"><o:p></o:p></span></span></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;tab-stops:&#10;191.4pt\">&nbsp;</p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><b><span lang=\"EN-US\">Additional documents:<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;<a href=\"https://ec.europa.eu/info/sites/default/files/research_and_innovation/research_by_area/documents/ec_rtd_global-health-edctp3-wp-annex1.pdf\" target=\"_blank\" style=\"font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; color: rgb(40, 151, 183); text-decoration-line: none;\">GH EDCTP3 JU Work Programme 2022</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><b><span lang=\"EN-US\"><o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/wp-call/2021-2022/wp-13-general-annexes_horizon-2021-2022_en.pdf\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Main Work Programme 2021&ndash;2022 &ndash; 13. General Annexes</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/rules-lev-lear-fca_en.pdf\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/aga_en.pdf\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\"><span lang=\"EN-US\">EU Grants AGA&nbsp;</span>&mdash; Annotated Model Grant Agreement</a></p>\r\n<p class=\"MsoNormal\" style=\"padding: 3px 0px; margin: 0px 0px 0.0001pt; line-height: 1.5; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\">&nbsp;&nbsp;</p>\r\n<ul style=\"padding: 0px; margin: 3px 0px 3px 30px; font-family: eui-light, &quot;Helvetica Neue&quot;, Helvetica, sans-serif; font-size: 12.6px; background-color: rgb(198, 219, 239);\">\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv%3AOJ.L_.2021.427.01.0017.01.ENG&amp;toc=OJ%3AL%3A2021%3A427%3ATOC\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">GH EDCTP3 JU Regulation of Establishment</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Programme guide</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021R0695\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Framework Programme and rules for Participation Regulation&nbsp; 2021/695</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32021D0764\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">HE Specific Programme Decision 2021/764</a></li>\r\n    <li style=\"padding: 0px; margin: 0px; color: rgb(51, 51, 51); line-height: 1.4; list-style-type: square;\"><a href=\"https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32018R1046&amp;qid=1535046024012\" target=\"_blank\" style=\"color: rgb(40, 151, 183); text-decoration-line: none;\">EU Financial Regulation</a></li>\r\n</ul>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\">&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><span lang=\"EN-US\">Funding &amp; Tenders Portal Online Manual</span></a><span lang=\"EN-US\"><o:p></o:p></span></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/tc_en.pdf\">Funding &amp; Tenders Portal Terms and Conditions</a><o:p></o:p></p>\r\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt\"><span style=\"font-size:11.0pt;line-height:115%;font-family:&quot;Calibri&quot;,sans-serif;&#10;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font:&#10;minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;&#10;mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:&#10;EN-US;mso-bidi-language:AR-SA\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/ftp/privacy-statement_en.pdf\">Funding &amp; Tenders Portal Privacy Statement</a></span></p>", "supportInfo": "<p><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;font-weight:normal;mso-bidi-font-weight:bold\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/om_en.pdf\"><b>Online Manual&nbsp;</b></a></span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">is your guide on the procedures from proposal submission to managing your grant.<o:p></o:p></span></p>\r\n<p><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/programme-guide_horizon_en.pdf\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Horizon Europe Programme Guide</span></b></a><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;</span></strong><strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif; font-weight: normal;\">contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq;type=undefined;categories=;programme=H2020;actions=;keyword=\" target=\"_blank\">Funding &amp; Tenders Portal FAQ</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;&ndash; find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/research-and-innovation/contact/research-enquiry-service_en\" target=\"_blank\">Research Enquiry Service</a></span>&nbsp;</b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.</span></p>\r\n<p><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></p>\r\n<p><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/ncp\" target=\"_blank\">National Contact Points (NCPs)</a>&nbsp;</span></b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (&lsquo;third-countries&rsquo;).<b><o:p></o:p></b></span></p>\r\n<p><a href=\"https://een.ec.europa.eu/\" target=\"_blank\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\">Enterprise Europe Network</span></b></a><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;&#10;color:#003366\">&nbsp;</span></strong><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/helpdesks/contact-form\" target=\"_blank\">IT Helpdesk</a></span></b>&nbsp;</span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&ndash;&nbsp;contact the Funding &amp; Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.<o:p></o:p></span></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://www.iprhelpdesk.eu/\" target=\"_blank\">European IPR Helpdesk</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;assists you on intellectual property issues.<br />\r\n<br />\r\n</span><b><a href=\"mailto:research@cencenelec.eu\" target=\"_blank\">CEN-CENELEC Research Helpdesk</a> and <a href=\"https://www.etsi.org/research/helpdesk\" target=\"_blank\">ETSI Research Helpdesk</a></b>&nbsp;<span style=\"font-family: Arial, sans-serif;\">&ndash;&nbsp;&nbsp;</span>the European Standards Organisations&nbsp;advise you how to tackle standardisation in your project proposal.&nbsp;&nbsp;</p>\r\n<p class=\"MsoNormal\" style=\"margin-left:36.0pt\"><o:p></o:p></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://euraxess.ec.europa.eu/sites/default/files/am509774cee_en_e4.pdf\" target=\"_blank\">The European Charter for Researchers and the Code of Conduct for their recruitment</a></span></b></span><strong><u><span style=\"font-size:&#10;9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366\"> </span></u></strong><strong><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif;color:#003366;font-weight:&#10;normal;mso-bidi-font-weight:bold\">&ndash; consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.</span></strong><b><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\"><o:p></o:p></span></b></p>\r\n<p><span class=\"MsoHyperlink\"><b><span style=\"font-size:9.0pt;font-family:&quot;Arial&quot;,sans-serif\"><a href=\"https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/partner-search\" target=\"_blank\">Partner Search Services</a></span></b></span><span style=\"font-size: 9pt; font-family: Arial, sans-serif;\">&nbsp;help you find a partner organisation for your proposal.<o:p></o:p></span></p>\r\n<p>&nbsp;</p>", "sepTemplate": "<p>To access the Electronic Submission Service, please click on the submission-button next to the <strong>type of action</strong> and the <strong>type of model grant agreement</strong> that corresponds to your proposal. You will then be asked to confirm your choice, as it cannot be changed in the submission system. Upon confirmation, you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Funding &amp; Tenders Portal and select the My Proposals page of the My Area section.</p>", "links": [], "additionalDossiers": [], "infoPackDossiers": [], "callDetailsJSONItem": {"additionalInfo": "", "staticAdditionalInfo": "<p>The general conditions relating to this call are those applicable to the 2021/2022 work programme of Global Health EDCTP3 outlined above.</p><p><u>Expected impacts of Call 1</u></p><p>Activities funded under this call for proposals should contribute to:</p><ul level=\"0\"><li>Achieve SDG3 \u2018Ensure healthy lives and promote well-being for all at all ages\u2019 in sub-Saharan African countries;</li><li>Provide evidence for informed health policies and guidelines within public health systems in sub-Saharan Africa and at international level;</li><li>Strengthen clinical research capability in sub-Saharan Africa to rapidly respond to emerging epidemics;</li><li>Enable a regulatory environment that can ensure effective development, delivery, and uptake of new or improved safe health technologies guaranteeing that trials in sub-Saharan African countries meet international standards;</li><li>Enable countries in sub-Saharan Africa to better understand pathogen epidemiology and support effective public health monitoring through integration of genomics and epidemiology;</li><li>Increase cost effectiveness of public investment through collaboration of funders of clinical trials in the area of infectious diseases in sub-Saharan Africa;</li><li>Strengthen health systems to ensure uptake of effective health technologies and innovations;</li><li>Enhance sustainable global scientific collaboration in health research and international cooperation across sub-Saharan Africa.</li> </ul>\n", "latestInfos": [{"approvalDate": "Dec 22, 2022 8:21:02 AM", "lastChangeDate": "Dec 22, 2022 8:21:02 AM", "content": "<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Information for the Funding Portal<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number proposals submitted: 92<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number Ineligible proposals: 11<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number proposals evaluated: 81<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Below threshold: 36<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Above threshold: 45<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Main list: 26<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number of Reserve list: 4<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Number rejected due to budgetary ressources: 15<o:p></o:p></span></b></p>\r\n<p class=\"MsoNormal\">&nbsp;</p>\r\n<p class=\"MsoNormal\"><b><span lang=\"EN-IE\" style=\"font-size:12.0pt;line-height:107%;mso-ansi-language:EN-IE\">Number of proposal upgraded from Reserve list to Main list: 1</span></b><span lang=\"EN-IE\"><o:p></o:p></span></p>"}, {"approvalDate": "May 17, 2022 4:30:46 PM", "lastChangeDate": "May 17, 2022 4:30:46 PM", "content": "The submission session is now available for: HORIZON-JU-GH-EDCTP3-2022-CALL1-01-01(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-04(HORIZON-JU-CSA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-03(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-02(HORIZON-JU-RIA), HORIZON-JU-GH-EDCTP3-2022-CALL1-01-05(HORIZON-JU-CSA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}